Know Cancer

forgot password

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Phase 3
18 Years
Open (Enrolling)
Thyroid Cancer

Thank you

Trial Information

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Inclusion Criteria


1. Subjects must have histologically or cytologically confirmed diagnosis of one of the
following differentiated thyroid cancer (DTC) subtypes:

a. Papillary thyroid cancer (PTC) i. Follicular variant ii. Variants (including but
not limited to tall cell, columnar cell, cribriform-morular, solid, oxyphil,
Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell
variant of papillary carcinoma, poorly differentiated) b. Follicular thyroid cancer
(FTC) i. Hürthle cell ii. Clear cell iii. Insular

2. Measurable disease meeting the following criteria and confirmed by central
radiographic review:

1. At least 1 lesion of ≥ 1.0 cm in the longest diameter for a non-lymph node or ≥
1.5 cm in the short-axis diameter for a lymph node which is serially measurable
according to RECIST 1.1 using computerized tomography/magnetic resonance imaging
(CT/MRI). If there is only one target lesion and it is a non-lymph node, it
should have a longest diameter of ≥ 1.5 cm

2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional
therapies such as radiofrequency (RF) ablation must show evidence of progressive
disease based on RECIST 1.1 to be deemed a target lesion

3. Subjects must show evidence of disease progression within 12 months (an additional
month will be allowed to accommodate actual dates of performance of screening scans,
i.e., within ≤ 13 months) prior to signing informed consent, according to RECIST 1.1
assessed and confirmed by central radiographic review of CT and / or MRI scans

4. Subjects must be 131I-refractory / resistant as defined by at least one of the

1. One or more measurable lesions that do not demonstrate iodine uptake on any
radioiodine scan

2. One or more measurable lesions that has progressed by RECIST 1.1 within 12
months of 131I therapy, despite demonstration of radioiodine avidity at the time
of that treatment by pre- or post-treatment scanning. These subjects must not
be eligible for possible curative surgery

3. Cumulative activity of 131I of > 600 mCi or 22 gigabequerels (GBq), with the
last dose administered at least 6 months prior to study entry

5. Subjects may have received 0 or 1 prior VEGF / VEGFR-targeted therapy ( for example
sorafenib, sunitinib, pazopanib, etc.)

6. Subjects with known brain metastases who have completed whole brain radiotherapy,
stereotactic radiosurgery or complete surgical resection, will be eligible if they
have remained clinically stable, asymptomatic and off of steroids for one month

7. Subjects must be receiving thyroxine suppression therapy and thyroid stimulating
hormone (TSH) should not be elevated (TSH should be ≤ 5.50 mcu/mL). When tolerated
by the subject, thyroxine dose should be changed to achieve TSH suppression (TSH <
0.50 mcu/mL) and this dose can be changed concurrently upon starting lenvatinib

8. All chemotherapy or radiation-related toxicities must have resolved to < Grade 2
severity, except alopecia and infertility

9. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of
0 − 2

10. Adequately controlled blood pressure with or without antihypertensive medications,
defined as BP < 150/90 mmHg at screening and no change in antihypertensive
medications within 1 week prior to Cycle 1 Day 1

11. Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min per
the Cockcroft and Gault formula

12. Adequate bone marrow function:

1. Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 × 103/μL)

2. Platelets ≥ 100,000/mm3 (≥ 100 × 109/L)

3. Hemoglobin ≥ 9.0 g/dL

13. Adequate blood coagulation function as evidenced by an International Normalized Ratio
(INR) ≤ 1.5

14. Adequate liver function:

1. Bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated
hyperbilirubinemia or Gilbert's syndrome

2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if subject has liver metastases).
if alkaline phosphatase is > 3 × ULN (in absence of liver metastases) or > 5 ×
ULN (in presence of liver metastases) AND the subject also is known to have bone
metastases, the liver-specific alkaline phosphatase must be separated from the
total and used to assess the liver function instead of total alkaline

15. Males or females age ≥ 18 years at the time of informed consent

16. All females must have a negative serum or urine pregnancy test. Females of
childbearing potential and male subjects who are partners of women of childbearing
potential must use or their partners must use a highly effective method of

17. Voluntary provision of written informed consent and the willingness and ability to
comply with all aspects of the protocol


1. Anaplastic or Medullary carcinoma of the thyroid

2. Two or more prior VEGF / VEGFR-targeted therapies or any ongoing treatment for
131I-refractory DTC other than TSH-suppressive thyroid hormone therapy

3. Prior treatment with lenvatinib (E7080)

4. Subjects who have received any anti-cancer treatment within 21 days or any
investigational agent within 30 days prior to the first dose of study drug and should
have recovered from any toxicity related to previous anti-cancer treatment. This
does not apply to the use of TSH-suppressive thyroid hormone therapy

5. Major surgery within 3 weeks prior to the first dose of study drug

6. Subjects having > 1+ proteinuria on urine dipstick testing will undergo 24h urine
collection for quantitative assessment of proteinuria. Subjects with urine protein ≥
1 g/24h will be ineligible

7. Gastrointestinal malabsorption, or any other condition in the opinion of the
investigator that might affect the absorption of lenvatinib (E7080). Significant
cardiovascular impairment: history of congestive heart failure greater than New York
Heart Association (NYHA) Class II, unstable angina; myocardial infarction or stroke
within 6 months of the first dose of study drug, or cardiac arrhythmia requiring
medical treatment

9. Prolongation of QTc interval to > 480 msec 10. Bleeding or thrombotic disorders or use
of anticoagulants, such as warfarin, or similar agents requiring therapeutic international
normalized ration (INR) monitoring. (Treatment with low molecular weight heparin (LMWH)
is allowed) 11. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3
weeks prior to the first dose of study drug 12. Active infection (any infection requiring
treatment) 13. Active malignancy (except for differentiated thyroid carcinoma, or
definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or
carcinoma in-situ of the cervix) within the past 24 months 14. Known intolerance to any of
the study drugs (or any of the excipients) 15. Any medical or other condition which, in
the opinion of the investigator, would preclude participation in a clinical trial 16.
Females who are pregnant or breastfeeding

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

To compare the Progression-free Survival (PFS) of subjects with 131IRefractory differentiated thyroid cancer (DTC) with radiographic evidence of disease progression within the prior 12 months treated with lenvatinib versus Placebo.

Outcome Time Frame:

Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first) as determined by blinded independent imaging review

Safety Issue:


Principal Investigator

Eisa Inc

Investigator Role:

Study Director

Investigator Affiliation:

Eisai Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

March 2011

Completion Date:

Related Keywords:

  • Thyroid Cancer
  • Thyroid Neoplasms
  • Thyroid Diseases



Hinsdale, Illinois  60521
Alexandria, Minnesota  56308
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Austin, Texas  78705
Seattle, Washington  98195
Flint, Michigan  48532
Louisville, Kentucky  40207
Little Rock, Arkansas  72205-7199
Omaha, Nebraska  68114
Hackensack, New Jersey  07601
Denver, Colorado  
Baltimore, Maryland  21287
Boston, Massachusetts  
Eugene, Oregon  
Milwaukee, Wisconsin  
Indianapolis, Indiana  
Lebanon, New Hampshire  
Charleston, West Virginia  25304
Washington, District of Columbia